DK1416965T3 - Assayfremgangsmåde til Alzheimers sygdom - Google Patents
Assayfremgangsmåde til Alzheimers sygdomInfo
- Publication number
- DK1416965T3 DK1416965T3 DK02766022T DK02766022T DK1416965T3 DK 1416965 T3 DK1416965 T3 DK 1416965T3 DK 02766022 T DK02766022 T DK 02766022T DK 02766022 T DK02766022 T DK 02766022T DK 1416965 T3 DK1416965 T3 DK 1416965T3
- Authority
- DK
- Denmark
- Prior art keywords
- disease
- alzheimer
- beta
- assay procedure
- preclinical
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31322401P | 2001-08-17 | 2001-08-17 | |
| US31322101P | 2001-08-17 | 2001-08-17 | |
| US33498701P | 2001-10-23 | 2001-10-23 | |
| PCT/US2002/026321 WO2003015617A2 (en) | 2001-08-17 | 2002-08-16 | Assay method for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1416965T3 true DK1416965T3 (da) | 2008-05-05 |
Family
ID=27405654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02766022T DK1416965T3 (da) | 2001-08-17 | 2002-08-16 | Assayfremgangsmåde til Alzheimers sygdom |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1416965B8 (enExample) |
| JP (2) | JP4511830B2 (enExample) |
| AT (1) | ATE381346T1 (enExample) |
| CA (1) | CA2457145C (enExample) |
| CY (1) | CY1107901T1 (enExample) |
| DE (1) | DE60224200T2 (enExample) |
| DK (1) | DK1416965T3 (enExample) |
| ES (1) | ES2295401T3 (enExample) |
| PT (1) | PT1416965E (enExample) |
| WO (1) | WO2003015617A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA006606B1 (ru) | 2000-02-24 | 2006-02-24 | Вашингтон Юниверсити | Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения |
| EP1944040B1 (en) | 2001-08-17 | 2012-08-01 | Washington University | Assay method for Alzheimer's disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| ES2344645T3 (es) | 2003-02-10 | 2010-09-02 | Applied Molecular Evolution, Inc. | Moleculas de union al abeta. |
| EP1480041A1 (en) * | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease |
| GB0519398D0 (en) * | 2005-09-23 | 2005-11-02 | Antisoma Plc | Biological materials and uses thereof |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008088983A1 (en) | 2007-01-18 | 2008-07-24 | Eli Lilly And Company | PEGYLATED Aβ FAB |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| JP5704533B2 (ja) * | 2009-02-13 | 2015-04-22 | 国立大学法人大阪大学 | アルツハイマー病の診断方法および診断薬 |
| EP2510359B1 (en) | 2009-12-11 | 2015-09-02 | Araclón Biotech, S. L. | Methods and reagents for improved detection of amyloid beta peptides |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| ES2874704T3 (es) * | 2013-11-20 | 2021-11-05 | Univ Iowa Res Found | Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE |
| CN109187981A (zh) * | 2018-08-01 | 2019-01-11 | 万东山 | 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用 |
| KR102496845B1 (ko) * | 2018-08-08 | 2023-02-08 | 서울대학교산학협력단 | 진단 지표로서 베타-아밀로이드 수준과 함께 혈장 타우 수준을 사용하는 알츠하이머병의 진단 및 치료 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994010569A1 (en) * | 1992-10-26 | 1994-05-11 | Schenk Dale B | METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6730778B2 (en) * | 1997-12-19 | 2004-05-04 | Pharmacia And Upjohn Company | Human sel-10 polypeptides and polynucleotides that encode them |
| EA006606B1 (ru) * | 2000-02-24 | 2006-02-24 | Вашингтон Юниверсити | Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения |
-
2002
- 2002-08-16 PT PT02766022T patent/PT1416965E/pt unknown
- 2002-08-16 DK DK02766022T patent/DK1416965T3/da active
- 2002-08-16 CA CA2457145A patent/CA2457145C/en not_active Expired - Fee Related
- 2002-08-16 AT AT02766022T patent/ATE381346T1/de active
- 2002-08-16 ES ES02766022T patent/ES2295401T3/es not_active Expired - Lifetime
- 2002-08-16 JP JP2003520382A patent/JP4511830B2/ja not_active Expired - Lifetime
- 2002-08-16 EP EP02766022A patent/EP1416965B8/en not_active Expired - Lifetime
- 2002-08-16 DE DE60224200T patent/DE60224200T2/de not_active Expired - Lifetime
- 2002-08-16 WO PCT/US2002/026321 patent/WO2003015617A2/en not_active Ceased
-
2008
- 2008-03-07 CY CY20081100267T patent/CY1107901T1/el unknown
-
2009
- 2009-09-09 JP JP2009208372A patent/JP5162553B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| PT1416965E (pt) | 2008-04-01 |
| EP1416965B8 (en) | 2008-02-13 |
| WO2003015617A3 (en) | 2004-01-29 |
| CY1107901T1 (el) | 2013-09-04 |
| DE60224200T2 (de) | 2008-07-10 |
| JP2004538477A (ja) | 2004-12-24 |
| EP1416965A2 (en) | 2004-05-12 |
| CA2457145C (en) | 2010-12-21 |
| ES2295401T3 (es) | 2008-04-16 |
| ATE381346T1 (de) | 2008-01-15 |
| JP5162553B2 (ja) | 2013-03-13 |
| EP1416965B1 (en) | 2007-12-19 |
| HK1061960A1 (en) | 2004-10-15 |
| WO2003015617A2 (en) | 2003-02-27 |
| JP4511830B2 (ja) | 2010-07-28 |
| DE60224200D1 (de) | 2008-01-31 |
| CA2457145A1 (en) | 2003-02-27 |
| JP2010044078A (ja) | 2010-02-25 |
| EP1416965A4 (en) | 2005-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107901T1 (el) | Μεθοδος προσδιορισμου για ασθενεια alzheimer | |
| EP1944040A3 (en) | Assay method for Alzheimer's disease | |
| EA200700083A1 (ru) | Антитела, направленные против бета-амилоидного пептида, и способы их применения | |
| DE60235746D1 (de) | Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation | |
| WO2001075454A3 (en) | Diagnosis and treatment of alzheimer's disease | |
| DK0749582T3 (da) | Fremgangsmåde til diagnosticering af præeklampsi | |
| DE69333076D1 (de) | Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis | |
| ATE234466T1 (de) | Verfahren zur feststellung von antipolymerantikörper und diagnosetestsatz zur feststellung von siliconabhängigen krankheiten | |
| ATE318328T1 (de) | Diagnostika und therapeutika für osteoporose | |
| ATE159300T1 (de) | Monoklonale antikörper gegen menschliches ige | |
| EP1017845A4 (en) | Diagnostic test for alzheimer's disease | |
| BRPI0407213A (pt) | Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados | |
| WO2002016636A3 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
| AU2003224120A1 (en) | Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases | |
| WO2004001422A3 (en) | Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases | |
| AU2002366555A1 (en) | Diagnostic for early stage alzheimer's disease | |
| DE50214523D1 (de) | Nukleotidträger zur diagnose und therapie oraler erkrankungen | |
| AU2003215667A1 (en) | Diagnostic and therapeutic use of human maguin proteins and nucleic acids for neurodegenerative diseases | |
| WO2002088345A3 (en) | Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene | |
| DE60229624D1 (de) | Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion | |
| FR2837284B1 (fr) | Methode de diagnostic serologique in vitro des endocardites infectieuses | |
| ATE261584T1 (de) | Plasmasammlungen von mehr als 200 gesunden patienten und davon abgeleiteter kalibrierstandard | |
| DE60111519D1 (de) | Chemische modifizierung von harn von säugern | |
| WO2006131562A3 (en) | Diagnostic and therapeutic target cdc2l6 gene and proteins for neurodegenerative diseases | |
| DK1414859T5 (da) | Monoklonale anti-SSRP-1-antistoffer og hybridomer som producerer antistofferne |